Clinical Trial Update: Phase III Study To Evaluate Alirocumab in Patients With Hypercholesterolemia Not Treated With a Statin (ODYSSEY CHOICE II) [Phase 3]

View source ↗

Summary

Phase III ODYSSEY CHOICE II evaluated alirocumab in patients with hypercholesterolemia not treated with a statin; results were posted in March 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypercholesterolemia

Drugs mentioned

• Praluent (alirocumab)

Snippet

Sponsor: Sanofi | Conditions: Hypercholesterolemia | Phase 3 | Status: COMPLETED | Results posted: 2017-03-15